GENMAB’S LIFE BEYOND DARZALEX (REDUCE, 8% DOWNSIDE)
29/05/20 -"A few months after our endorsement in March 2019, Genmab (Reduce, Denmark) made a big splash on Nasdaq with one of the biggest IPOs in biotech history – it raised c.$500m (c.5% of the share capital) ..."
Pages
51
Language
English
Published on
29/05/20
You may also be interested by these reports :
03/05/24
Genmab’s Q1 sales exceeded expectations, although profitability fell somewhat short. This robust performance was led by strong growth across all the ...
03/05/24
We have rolled forward our model to include a new forecast year (2026) which will also see continued healthy top-line growth and profitability ...
02/05/24
CureVac did not really tidy things up. The cost-cutting measures, as presented, are insufficient and do not meet our ideal scenario of a focused and ...
02/05/24
The Q1 results exceeded the street’s expectations, driven by the strong momentum for Novo’s diabetes and obesity offerings. While the management ...